AMPH today
$28.60-$0.46 (-1.58%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourAscending Triangle
15 minSymmetric Triangle
5 minExpanding
Daily trend turns down below $16.64
Key levels
Resistance$31.26
Resistance$29.23
Support$27.80
Support$26.61
Latest news & SEC filings
NewsAmphastar Pharmaceuticals CFO sells company stock
AnalystWells Fargo keeps Equal-Weight on Amphastar Pharma, lifts target to $25
NewsAmphastar Pharmaceuticals board adds $50M to share buyback program
All AMPH news →About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals develops, manufactures, and sells generic and proprietary prescription medicines given by injection, inhaled through the mouth, or sprayed into the nose, plus active pharmaceutical ingredients. Its offerings include a nasal glucagon powder for severe low blood sugar, a nonprescription epinephrine inhaler, emergency injections such as glucagon, epinephrine, and naloxone, an anticoagulant, and an asthma inhaler. It serves hospitals, wholesalers, and other customers, primarily in the United States and several other countries.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Amphastar Pharmaceuticals, Inc. (AMPH)
What Is the Price Target for AMPH?
SEPT Low Target
$20.00
SEPT Mid Target
$20.50
SEPT High Target
$23.00
Analyst Consensus
$20.50
Is AMPH a Buy or Sell Right Now?
Thesis
- •Revenue growing -1.6% YoY with STABLE trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AMPH.
Start Free Trial →Is AMPH Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$26.95
47
Moat Score
NARROW
6/9
Piotroski Score
2.6
Altman Z-Score
What Is Smart Money Doing with AMPH?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| PETERS WILLIAM J | director officer | Buy | 11,000 | $198K | Nov 5, 2026 |
| PETERS WILLIAM J | director officer | Sale | 12,631 | $366K | Nov 5, 2026 |
| PETERS WILLIAM J | director officer | Buy | 16,000 | $208K | Nov 4, 2026 |
| PETERS WILLIAM J | director officer | Sale | 16,000 | $448K | Nov 4, 2026 |
| PETERS WILLIAM J | director officer | Sale | 4,139 | $103K | Sep 21, 2026 |
| Lee Howard | director | Sale | 769 | $14K | Jun 2, 2026 |
| Gaugh David Russell | director | Buy | 8,143 | - | Jun 1, 2026 |
| Deflin Gayle | director | Buy | 8,143 | - | Jun 1, 2026 |
| Gerst Diane G. | director | Buy | 8,143 | - | Jun 1, 2026 |
| Lee Howard | director | Buy | 8,143 | - | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AMPH Growth Story
Revenue YoY
-1.6%
3yr Revenue CAGR
13.0%
EPS Growth YoY
-33.66%
FCF Growth YoY
-29.7%
Revenue Trend
STABLE
Dark Pool Trades for AMPH
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AMPH, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:07 | $28.60 | 1,075 | $$31K | BUY |
| 21:00:57 | $28.60 | 6,200 | $$177K | BUY |
| 21:00:25 | $28.60 | 3,032 | $$87K | SELL |
| 21:00:00 | $28.60 | 89,282 | $$2.6M | MIDPOINT |
| 19:10:35 | $29.05 | 1,500 | $$44K | MIDPOINT |
5 dark pool trades shown · $$2.9M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Amphastar Pharmaceuticals, Inc. (AMPH) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AMPH — frequently asked questions
What is AMPH stock price today?
Amphastar Pharmaceuticals, Inc. (AMPH) is at $28.60, down 1.58% (-$0.46) at the Nov 11, 2026 close.
Why is AMPH stock moving today?
Latest AMPH news — Nov 7, 2026: Amphastar Pharmaceuticals CFO sells company stock · Nov 6, 2026: Wells Fargo keeps Equal-Weight on Amphastar Pharma, lifts target to $25
What is the AMPH price target?
The average analyst price target for AMPH is $20.50, ranging from $20 to $23, based on 6 analysts. Latest: Piper Sandler maintains on Aug 7, 2026.
What do analysts rate AMPH?
Analyst ratings for AMPH: 0 Buy, 3 Hold, 3 Sell — consensus Hold.
Did AMPH beat earnings?
AMPH last reported on Nov 5, 2026: EPS $1.14 vs $0.86 expected — a beat of 32.7%.
What is AMPH's P/E ratio?
AMPH trades at a P/E of 16.6 vs a Healthcare average of 18.5.
Does AMPH pay a dividend?
AMPH does not currently pay a dividend.
How much debt does AMPH have?
Amphastar Pharmaceuticals, Inc. reported $610M of debt and $224M of cash (Jun 30, 2026).
What are AMPH support and resistance levels?
Support: $27.80, $26.61, $24.62. Resistance: $29.23, $31.26, $32.69.
What are insiders doing with AMPH?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on AMPH?
Nov 7, 2026: Amphastar Pharmaceuticals CFO sells company stock · Nov 6, 2026: Wells Fargo keeps Equal-Weight on Amphastar Pharma, lifts target to $25 · Nov 5, 2026: Amphastar Pharmaceuticals board adds $50M to share buyback program